Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


FDA approves expanded indication for Ervebo in Zaire ebolavirus – Merck Inc

Written by | 11 Aug 2023

Merck Inc announced that the FDA has approved an expanded indication for Ervebo, which is now indicated for the prevention of disease caused by Zaire ebolavirus in individuals… read more.

Trial on safety and immunogenicity of Ebola vaccines yields promising results

Written by | 17 Dec 2022

Ebola epidemics occur periodically in various sub-Saharan African countries. While vaccines exist and have already received WHO Prequalification[1] against the Zaire ebolavirus species, it is essential to pursue and intensify efforts to… read more.

Ebola Vaccine Regimen demonstrated robust and durable immune response in adults and children in data published in The Lancet Infectious Diseases – Johnson & Johnson

Written by | 7 Oct 2021

Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo), generated robust… read more.

Ebola vaccine regimen generates strong immune response in children and adults in a clinical trial in Sierra Leone

Written by | 21 Sep 2021

Results support the use of Johnson & Johnson’s vaccine regimen for Ebola virus disease LONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE Johnson & Johnson’s two-dose Ebola vaccine regimen… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.